Angiotensin II (GIAPREZA)
Refractory Hypotensive Shock
ApprovedMarketed (Pre-Insolvency)
Key Facts
About Paion
PAION AG was a publicly listed German biopharmaceutical company focused on hospital-based sedation, anesthesia, and critical care. Its core achievement was the development and global regulatory approval of remimazolam, a novel, controllable benzodiazepine sedative. The company pursued a hybrid strategy of internal development and strategic in-licensing (e.g., GIAPREZA, XERAVA) but ultimately entered insolvency proceedings in January 2024, leading to the sale of its operating assets to a new entity, PAION Pharma GmbH.
View full company profile